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The macrophage in HIV-1 infection: From
activation to deactivation?
Georges Herbein1*, Audrey Varin1,2
Abstract
Macrophages play a crucial role in innate and adaptative immunity in response to microorganisms and are an
important cellular target during HIV-1 infection. Recently, the heterogeneity of the macrophage population has
been highlighted. Classically activated or type 1 macrophages (M1) induced in particular by IFN-g display a pro-
inflammatory profile. The alternatively activated or type 2 macrophages (M2) induced by Th-2 cytokines, such as
IL-4 and IL-13 express anti-inflammatory and tissue repair properties. Finally IL-10 has been described as the proto-
typic cytokine involved in the deactivation of macrophages (dM). Since the capacity of macrophages to support
productive HIV-1 infection is known to be modulated by cytokines, this review shows how modulation of macro-
phage activation by cytokines impacts the capacity to support productive HIV-1 infection. Based on the activation
status of macrophages we propose a model starting with M1 classically activated macrophages with accelerated
formation of viral reservoirs in a context of Th1 and proinflammatory cytokines. Then IL-4/IL-13 alternatively acti-
vated M2 macrophages will enter into the game that will stop the expansion of the HIV-1 reservoir. Finally IL-10
deactivation of macrophages will lead to immune failure observed at the very late stages of the HIV-1 disease.
Introduction
Macrophages (Ms) are the first line of defence of
the organism against pathogens and, in response to the
microenvironment, become differentially activated. The
classical pathway of interferon-g-dependent activation of
macrophages (M1) by T helper 1 (Th1)-type responses
is a well-established feature of cellular immunity to
infection with HIV-1. In the presence of cytokines that
are produced in a Th-2 type response, such as IL-4 and
IL-13, macrophages become differentially activated (M2)
and play an important role in HIV-1 pathogenesis.
Although it is superficially similar to a Th2-type cyto-
kine and is often co-induced with Th2 cytokines in the
course of an immune response, it is not appropriate to
classify IL-10 together with IL-4 and IL-13 as an alter-
native activator of macrophages. IL-10 acts on a distinct
plasma membrane receptor to those for IL-4 and IL-13
[1], and its effects on macrophage gene expression are
different, involving a more profound inhibition of a
range of antigen-presenting and effector functions, lead-
ing to a deactivation stage of macrophages [2]. Follow-
ing this line of reasoning, it seems appropriate to
classify macrophages in IFN-g classically activated
macrophages (M1), IL-4/IL-13 alternatively activated
macrophages (M2), and IL-10 deactivated macrophages
(dM). In addition, T cells themselves are more heteroge-
neous than was thought originally [3,4], including not
only Th0, Th1 and Th2 type cells, but also among other
regulatory (Treg) and Th17 cells [5]. In addition, a wide
variety of stimuli, both endogenous and exogenous,
influence the susceptibility of macrophages to infection
by HIV-1. The differentiation stage of monocytes/
macrophages also modulates permissiveness to HIV-1:
primary monocytes are less susceptible to the virus than
differentiated macrophages [6-9]. The localization of
macrophages in different tissues results in cells with dis-
tinct activation status and susceptibility to HIV-1 infec-
tion. Addressing the effects of macrophage differentiation
and/or activation on HIV-1 replication provides some
insight into the impact of specific microenvironments on
macrophage infection in vivo. Modulation of HIV-1 repli-
cation induced by diverse stimuli have however been
addressed using monocytic cell lines, primary monocytes
or macrophages differentiated in vitro from primary
monocytes. Keeping these data in mind, the present
review will focus on the distinctive patterns of macro-
phage activation (classically activated M1, alternatively
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activated M2, and deactivated dM) in HIV-1
pathogenesis.
Classical Activation of Macrophages and HIV-1
Infection
Classically activated or type 1 macrophages induced in
particular by IFN-g [10], display a pro-inflammatory
profile (Figure 1). In addition pro-inflammatory cyto-
kines modulate HIV-1 replication in macrophages and
could depend on the maturation and/or activation stages
of monocytes/macrophages [7,8]. High levels of proin-
flammatory cytokines, such as tumor necrosis factor a
(TNFa), interleukin (IL)-1b and IL-6 in both plasma
and lymph nodes are observed from the early stages of
HIV-1 infection [11-15]. The secretion of chemokines
such as macrophage inflammatory protein (MIP)-1a,
MIP-1b and RANTES (CCL3, CCL4 and CCL5 respec-
tively) is increased in these patients [16,17]. Immune
activation also reflects the mounting of antiviral immu-
nity with enhanced Th1 activity and increased levels of
IFNg, IL-12, IL-2 and IL-18, especially in lymph nodes
of HIV-infected subjects [18]. In addition these cyto-
kines and their receptors have validated the importance
of this pathway in cellular immunity, immunodeficiency
syndromes, delayed hypersensitivity responses and tissue
damage [2]. In classically activated macrophages, the fol-
lowing steps of the HIV-1 life cycle are modulated
(Table 1).
Entry
HIV-1 infects monocytes/macrophages via interaction of
gp120 with CD4 and either coreceptor CXCR4 or CCR5
which determines the cellular tropism [19-31]. HIV-1
envelope glycoprotein gp120 down-regulates CD4
expression in primary human macrophages through
induction of endogenous TNFa [32-37]. TNFa, IL-1b
and IFN-g down-regulate both surface and total CD4
expression in primary human macrophages at the level
of transcription [36,38-41]. TNFa, IFN-b, and IFN-g
inhibit R5 and R5/X4 HIV-1 entry into primary macro-
phages via down-regulation of both cell surface CD4
and CCR5 and via enhanced secretion of C-C chemo-
kines, MIP-1a, MIP-1b, and RANTES [37,38,40,42-46].
An iterative pre-treatment of primary macrophages with
TNFa prior to HIV infection inhibits HIV-1 replication
[43]. The inhibition of HIV-1 entry into primary macro-
phages by TNFa involves the 75-kDa TNFR2 [43].
Another explain could be that TNFa triggers the release
Figure 1 Classical activation (M1), alternative activation (M2) and deactivation of macrophages. Classical activation is mediated by the
priming stimulus IFN-g, followed by a microbial trigger (lipopolysaccharide, LPS). Alternative activation is mediated by IL-4 and IL-13, acting
through a common receptor chain (IL-4Ra). Deactivation can be innate or acquired in origin. The uptake of apoptotic cells or lysosomal storage
of host molecules generates anti-inflammatory responses. Cytokines (IL-10, TGF-b, M-CSF, IFNa/b) and glucocorticoids are potent modulators of
activation. Pathogens can deactivate macrophages by various mechanisms.
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of granulocyte-macrophage colony-stimulating factor
(GM-CSF) that has been reported to down-regulate
CCR5 and subsequently block entry of R5 HIV into
macrophages [47]. Interestingly, TNFR2 stimulation trig-
gers GM-CSF secretion that has been shown to block
R5 HIV-1 entry via CCR5 downregulation [47]. The
inhibition of HIV-1 entry into macrophages observed
following TNFa pre-treatment could be mediated via
the secretion of C-C chemokines, such as RANTES,
MIP-1a and MIP-1b. TNFa induces the production of
RANTES, MIP-1a, and MIP-1b which in turn down-
regulate cell surface CCR5 expression on primary
macrophages resulting in inhibition of R5 HIV-1 entry
[48-53]. In agreement with this observation, RANTES
inhibits HIV-1 envelope-mediated membrane fusion in
primary macrophages [54] and the activity of RANTES
promoter that contains four NF-kB binding sites is up-
regulated by TNFa [55]. Nevertheless, some authors
report an enhancement of HIV-1 replication by
RANTES in primary macrophages [27,56]. The enhan-
cing effect of RANTES on HIV-1 infectivity may be
independent of the route of virus-cell fusion and could
involve two different mechanisms: one mediated via cel-
lular activation, and the other mediated via increased
virion attachment to target cells [56]. Another explana-
tion for this discrepancy is the activation and/or differ-
entiation status of macrophages with a more potent
inhibitory effect of RANTES on monocyte-derived
macrophages cultivated in vitro in absence of additional
cytokines such as M-CSF [57].
The monocyte chemotactic protein-2 (MCP-2), but
not MCP-1, has been shown to bind to CCR1, CCR2b,
and CCR5 and to inhibit CD4/CCR5-mediated HIV-1
entry/replication [58]. Pretreatment of macrophages
with IL-16 also inhibits R5 and R5/X4 HIV-1 replication
in primary macrophages at the level of entry, although
the secretion of CC-chemokines does not seem to be
involved in this phenomenon [59].
IL-2 has been reported to inhibit HIV-1 replication in
macrophages by down-regulating CD4 and CCR5
expression [60]. IL-15 is a Th1 cytokine produced by
mononuclear phagocytes and shares many activities with
IL-2, such as T-cell proliferation and activation. In addi-
tion IL-15 is more potent than IL-2 in stimulating NK
cell function, including secretion of IFN-g and of CCR5-
binding chemokines [61]. Ex vivo, increased levels of IL-
15 were detected in histocultures established from
lymph nodes of individuals who were HIV positive in
comparison to their uninfected counterparts [62]. Super-
natants of NK cells stimulated with IL-12 and IL-15
inhibited both macrophage-tropic HIV-1NFN-SX and T
cell-tropic HIV-1NL4-3 replication in vitro, but not dual-
tropic HIV-189.6 due to the use of multiple coreceptors
for entry by this latter, including CXCR4, CCR5, but
also CCR3 and CCR2b [24,63]. Importantly, the C-C
chemokines MIP-1a, MIP-1b, and RANTES were
responsible only for a fraction of the HIV-1-suppressive
activity exhibited by NK cell supernatants against
macrophage-tropic HIV-1. Collectively these data indi-
cate that NK cells from normal and HIV-1+ donors
Table 1 HIV-1 viral cycle in classically activated M1, alternatively activated M2 and deactivated macrophages
Viral cycle
target
M1 macrophages M2 macrophages Deactivated macrophages
Entry Decreased * CD4 downregulation: TNFa, IL1b, IFNg, IL-
2, IL-18
Decreased * CXCR4
downregulation: IL-4,
IL-13
Decreased * CCR5 downregulation:
IFNb
* CCR5 downregulation: TNFa, MIP-1a, MIP-
1b, MCP-2, RANTES, IFNg, GM-CSF, IL-2, IL-
16, IL-15
* CCR5
downregulation IL-13
Increased * CCR5 upregulation: IL-10,
M-CSF
* fusion block: RANTES * CD4
downregulation IL-13
Reverse
transcription
No effect
reported
Decreased * Block of RT: IL-13 Decreased * Block of RT: IL-10, IFNa/b
* Inhibition of RT synthesis:
TGFb
Transcription Increased *Transactivation of HIV-1 LTR: TNF, IL-1b, IL-
6, GM-CSF, IL-18
Decreased
+
* Block of HIV-1 LTR
transactivation: IL-4,
IL-13
Decreased * Block of HIV-1 LTR
activation ++
Post
transcription
Decreased * Inhibition of viral assembly and budding:
IFNg, IL-18 (via IFNg release),
No effect
reported
Decreased * Inhibition of viral
assembly: IL-10
* Inhibition of viral budding:
IFNa/b, IL-27 (via IFNa
release)
+ inhibition in differentiated macrophages
++ depends on IL-10 concentration
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produce C-C chemokines and other unidentified factors
that can inhibit both macrophage- and T cell-tropic
HIV-1 replication in vitro [63].
IL-18 is a pro-inflammatory cytokine related to the IL-
1 family of cytokines that plays an important role in
both innate and adaptative immune responses against
viruses [64,65]. Increased levels of circulating IL-18
from HIV-1 infected patients have been reported espe-
cially in the advanced and late stages of the disease [65].
IL-18 reduces cell surface expression of the HIV-1
receptor CD4 [66]. In the advanced stages of the disease,
strong activation of IL-18 production along with persis-
tent decreased production of IFN-g, IL-12 and IL-2 may
promote a Th2 immune response, which leads to persis-
tent viral replication [65].
CD40 ligand (CD40L) is a cell surface molecule of
CD4+ T cells that interacts with its receptor CD40 on
antigen-presenting cells (APC) to mediate thymus-
dependent humoral immunity and inflammatory reac-
tions. The stimulation of macrophages by CD40L has
been shown to trigger the release of TNFa and CC-che-
mokines which results in down-regulation of cell surface
CD4 and CCR5 and subsequent inhibition of HIV-1
entry into macrophages [17,67-69]. An in situ hybridiza-
tion study showed that macrophages in lymph nodes of
HIV-1 infected individuals produce MIP-1a and MIP-
1b, and to a lesser extent RANTES, suggesting that
HIV-1 infection might be modulated in vivo by activated
macrophages [70]. It is interesting to note that the
CD40/CD40L interaction triggers signalling through
TNF receptor-associated factor 6 (TRAF6) in antigen
presenting cells. TRAF6 has also been involved in innate
immune responses mediated by TLR-4, such as the
response to lipopolysaccharide (LPS) [68]. Like CD40L
activation, LPS stimulation also induces high secretion
of C-C chemokines and TNFa and inhibits infection of
macrophages and CD4+ T cells with R5 HIV-1 strains.
Thus, during opportunistic infections, LPS might also be
produced that, either directly or indirectly via TNFa
production, might block HIV-1 entry into macrophages
[71,72]. In human blood monocyte tissue culture-
derived macrophages (TCDM), endogenous TNFa and
IL-1b induced by LPS, down-regulate surface and total
CD4 expression in primary macrophages [41]. Conver-
sely, neither LPS nor TNFa/IL-1b were able to modulate
surface CD4 expression on quiescent or PHA-activated
lymphocytes [41]. Thus, opportunistic infections during
HIV disease can result in a sustained but controlled viral
production within infected macrophages.
Transcription
TNFa has been reported to stimulate HIV-1
replication in chronically infected promonocytic U1
cell line through NF-kB activation and subsequent
transactivation of the proviral LTR [73-76]. The stimula-
tion of HIV-1 replication in U1 cell line with TNFa is
mediated through the TNFR1, and not via TNFR2 [77].
Similarly, IL-1b binding to the IL-1 receptor 1, but not
to the IL-1 receptor 2, stimulates HIV-1 transcription
through activation of NF-kB or by an independent
mechanism [75,78]. IL-1 can act alone or in synergy
with IL-6 to stimulate viral replication in chronically
infected promonocytic U1 cell line [78]. In addition IL-6
alone stimulates HIV-1 replication in U1 cells and pri-
mary macrophages infected with R5 AD-87 strain, but
not in T cell lines [76]. Nuclear factor IL-6 (NF-IL6) is
a nuclear factor that activates gene expression in
response to IL-6. A consensus binding site for NF-IL6 is
present in the LTR of many HIV-1 variants and the reg-
ulation of HIV-1 LTR by NF-IL6 and NF-kB/Rel tran-
scription factors has been reported [79-81]. IL-6
stimulates HIV replication by activating viral transcrip-
tion in synergy with TNFa and also by targeting a post-
transcriptional step [76]. In addition, endothelial cells
enhance C/EBPbeta binding activity and HIV-1 replica-
tion in macrophages. This increase in HIV-1 transcrip-
tion is due in part to the production of soluble factors,
such as IL-6 and also is mediated by ICAM-1 activation
[82], indicating that endothelial cells, through the activa-
tion of C/EBPb, provide a microenvironment that sup-
ports HIV-1 replication in monocytes/macrophages. The
stimulation of HIV-1 replication in primary macro-
phages by GM-CSF is primarily due to enhanced viral
transcription rather than increased viral entry [76]. GM-
CSF stimulates HIV-1 replication in promonocytic U1
cells [83] and in primary human macrophages infected
with the R5 HIV-1 JR-FL strain [84] by targeting HIV
LTR at a site different from NF-B [76].
In vitro, both acute HIV infection and incubation of
the THP-1 monocytoid cell line with the accessory viral
protein Nef induced expression of IL-18 [85]. Like most
proinflammatory cytokines, IL-18 induces HIV expres-
sion in chronically infected monocytic cell lines via
induction of the release of endogenous TNFa and IL-6
[86]. IL-18 stimulates HIV-1 replication in the chroni-
cally infected U1 monocytic cells, mediated in part via
TNFa and IL-6 since the addition of anti-TNFa and
anti-IL-6 antibodies reduced IL-18 increased HIV-1 pro-
duction by 48% and 63%, respectively [86]. IL-18 stimu-
lation of HIV-1 replication in U1 cells involves NF-kB
and p38 MAPK activation [86].
Posttranscription
The effect of IFN-g on HIV-1 replication might be
more complex. Pretreatment of human primary macro-
phages with IFN-g before viral input has been reported
either to stimulate or to inhibit HIV-1 replication
[45,46,84]. In addition, IL-18 has been reported as an
Herbein and Varin Retrovirology 2010, 7:33
http://www.retrovirology.com/content/7/1/33
Page 4 of 15
IFN-g-inducing factor which inhibits HIV-1 production
in PBMC through IFN-g [66].
Altogether classically activated macrophages M1 are in
contact with Th1 cytokines (IFN-g, IL-2, IL-12), proin-
flammatory cytokines (TNFa, IL-1b, IL-6, IL-18) and
chemokines (MIP-1a, MIP-1b, RANTES) that favor the
formation of viral reservoirs with inhibition of HIV-1
entry, assembling and budding parallel to increased
viral transcription within the infected macrophages
(Figure 2).
Alternative Activation of Macrophages and HIV-1
Infection
The alternatively activated or type 2 macrophages (M2)
induced by Th-2 cytokines, express anti-inflammatory
and tissue repair properties [2] (Figure 1). Alternative
activation of macrophages is induced by IL-4 and IL-13,
cytokines that are produced in a Th-2 type response,
particularly during allergic, cellular and humoral
responses to parasitic and selected pathogen infections.
The alternative activation of macrophages is mediated
by IL-4 and IL-13, acting through a common receptor
chain (IL-4Ra) [87]. IL-4 is a pleiotropic cytokine pro-
duced by a subpopulation of CD4+ T cells, designated
Th-2 cells, and by basophiles and mast cells. IL-4 modu-
lates other lymphoid cell activities such as regulation of
the differentiation of antigen-stimulated T lymphocytes
[88,89] and control of immunoglobulin class switching
in B lymphocytes [90-93]. IL-13 is a cytokine secreted
by activated T cells which has been shown to be a
potent in vitro modulator of human monocytes and B
cell functions [94-96]. Among its pleiotropic activities,
IL-13 induces significant changes in the phenotype of
human monocytes, up-regulating their expression of
multiple cell surface molecules and increasing their anti-
gen presenting capabilities. IL-4 and IL-13 upregulate
expression of the mannose receptor and MHC class II
molecules by macrophages which stimulate endocytosis
and antigen presentation, and they induce the expres-
sion of macrophage-derived chemokine (MDC, also
known as CCL22). IL-4 and IL-13 augment expression
of IL-1 decoy receptor and the IL-1 receptor a-chain in
vitro and in vivo, thereby counteracting the proinflam-
matory actions of IL-1 [97,98]. In alternatively activated
macrophages, the following steps of the HIV-1 life cycle
are modulated (Table 1).
Entry
Infection of macrophages by primary R5X4 and X4 iso-
lates of HIV-1 is inhibited by IL-4 and IL-13, an effect
that is associated with down-regulation of surface
CXCR4, CCR5 and CD4 expression [38,99].
Reverse transcription
Upon cell infection by HIV-1, the reverse transcriptase
copies the genomic RNA to generate the proviral DNA
flanked by two LTRs [100]. IL-13 has been shown to
inhibit HIV-1 replication in blood-derived monocytes
Figure 2 A model of HIV-1 pathogenesis based on the activation status of macrophages.
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and mature lung macrophages, but not in T cells
[95,101]. The mechanism by which IL-13 inhibits HIV-1
is not yet clear. IL-13 has been reported either not to
modulate reverse transcription [102] or to block the
completion of reverse transcription in macrophages
[103].
Transcription
IL-13 has been reported to block HIV-1 replication at
the level of transcription in human alveolar macro-
phages [102]. In fact, the state of maturation of mono-
cytes into macrophages determines the effects of IL-4
and IL-13 on HIV-1 replication. In freshly isolated
monocytes, IL-4 up-regulates the expression of both
genomic and spliced HIV mRNA [104,105]. IL-4 stimu-
lates NF-B translocation and binding resulting in
enhanced HIV RNA expression [105]. IL-4 up-regulates
the expression of HIV mRNA within the first two days
after infection of promonocytic U937 cells and 3 to 4
days after infection of plastic-adherent blood-derived
macrophages with HIV-1 [104,106]. Conversely, IL-13
and IL-4 inhibit HIV-1 replication at the transcriptional
level in differentiated macrophages, but not in periph-
eral blood lymphocytes [95,104,105]. In addition, expo-
sure to IL-13 inhibits the transcription of many other
cytokines in monocytes, including IL-1a, IL-1b, IL-6,
TNF, and GM-CSF [96], all of which have been impli-
cated in enhancing HIV-1 replication in vitro [107-110].
Altogether alternatively activated macrophages are in
contact with IL-4/IL-13 producing Th2 cells that will
curtail the formation of HIV-1 reservoirs in the macro-
phages (Figure 2).
Deactivation of Macrophage and HIV-1 Infection
The prototypic cytokine involved in the deactivation of
macrophages is IL-10. Although it is superficially simi-
lar to a Th2-type cytokine and is often co-induced with
Th2 cytokines in the course of an immune response, it
is not appropriate to classify IL-10 together with IL-4
and IL-13 as an alternative activator of macrophages
[2]. IL-10 acts on a distinct plasma membrane receptor
to those for IL-4 and IL-13 [1]. Similar to IL-10, other
cytokines such as TGF-b, M-CSF and IFNa/b result in
macrophage deactivation [2] with strong anti-inflam-
matory properties, down-regulation of MHC class II
molecules on the plasma membrane (Figure 1). Deacti-
vation of macrophages leads to immune suppression
through at least two independent mechanisms: dimin-
ished MHC class II expression and increased uptake of
apoptotic cells generating an anti-inflammatory
response [111-115]. In deactivated macrophages, the
following steps of the HIV-1 life cycle are modulated
(Table 1).
Entry
IL-10 up-regulates cell surface CCR5 expression on
monocytes and thereby enhances viral entry [116]. M-
CSF has been shown to favor HIV-1 replication in
human macrophages, probably via an increased matura-
tion stage and increased CCR5 expression, also resulting
in enhanced viral entry [29,117]. By contrast, IFN-b
inhibit R5 HIV-1 entry into primary macrophages via
down-regulation of both cell surface CD4 and CCR5
and via enhanced secretion of C-C chemokines, MIP-
1a, MIP-1b, and RANTES [37,40,42-46].
Reverse transcription
IL-10 suppresses HIV-1 replication in primary human
macrophages by inhibiting the initiation of reverse tran-
scription; therefore, IL-10 mediates a virostatic latent
stage in cells of the monocyte/macrophage lineage
[118-120]. TGF-b inhibits the synthesis of different viral
proteins especially reverse transcriptase in U1 promono-
cytic cells activated by phorbol ester or IL-6 [121].
Members of the APOBEC (acronym for apolipoprotein
B editing catalytic polypeptide) family of cellular cytidine
deaminases represent a recently identified group of pro-
teins that provide immunity to infection by retroviruses
[122-125]. The cytidine deaminases APOBEC exert anti-
HIV-1 activity that is countered by the HIV-1 vif pro-
tein [122]. Tripartite motif (TRIM) proteins constitute a
family of proteins that share a conserved tripartite archi-
tecture [126-128]. Interferons, especially type I IFNa/b
bolster innate defence against HIV-1 via the up-regula-
tion of APOBEC/TRIM proteins which blocks retroviral
replication, especially reverse transcription [129-131].
Transcription
High concentrations of IL-10 inhibit the production of
proinflammatory cytokines such as TNFa, IL-1b, IL-6,
and thereby IL-10 inhibits HIV-1 transcription [132]. By
contrast, low concentrations of IL-10 have been
reported to enhance HIV replication in macrophages
induced by TNF-a and IL-6 via an increase in HIV
mRNA accumulation and stimulation of phorbol ester-
induced LTR-driven transcription that is independent of
the NF-B and Sp1 transcription factors [133].
Posttranscription
Primary macrophages treated with IL-10 after HIV-1
inoculation show an accumulation of Gag protein sug-
gestive of an inhibitory effect at the level of virus assem-
bly [134]. IFNa and IFNb reduce HIV-1 replication in
primary macrophages although inhibition by IFNa has
been reported to be more efficient [45,135]. Anti-HIV
effects of IFNa/b are mediated by both inhibition of
viral assembly and budding [136,137]. IL-27 inhibits
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HIV replication in monocyte-derived macrophages like
IFN-a and IFN-b[138]. IL-27 suppresses the transcrip-
tion of HIV-1 and preferentially inhibits HIV-1 replica-
tion in macrophages compared with CD4+ T cells and
activates multiple IFN-inducible genes (ISG) in macro-
phages like IFN-a, suggesting that IL-27 inhibits HIV-1
replication in macrophages via a mechanism similar to
that of IFN-a [138-140]. Recently, of the hundred of
IFN-inducible genes discovered to date, ISG15 and
ISG20 have been reported to inhibit assembly and
release of HIV-1 virions [141-144]. In addition the IFN-
inducible tripartite motif protein TRIM22 inhibits the
budding of HIV-1 with diffuse cytoplasmic distribution
of Gag rather than accumulation at the plasma mem-
brane [145]. The effects of TGF-b on the post-transcrip-
tional steps of HIV-1 replication are more complex. In
primary human macrophages, both inhibition and sti-
mulation of HIV-1 replication have been reported fol-
lowing a posttreatment with TGF-b[121,146].
Altogether in deactivated macrophages, HIV-1 replica-
tion is strongly blocked at several steps of the viral life
cycle especially reverse transcription, transcription and
viral budding and assembly (Figure 2).
Activation Status of Macrophages and HIV-1
Pathogenesis
Because of the various behaviours of macrophages
reported (classically activated M1, alternatively activated
M2, deactivated dM), we would like to present a new
model that highlights the role of macrophage activation
status in the modulation of viral persistence and T-cell
apoptosis and could thereby further enhance our under-
standing of pathogenesis of HIV-mediated disease (Fig-
ure 2). We will first propose a model that applies to the
monocytes/macrophages present in the blood and in the
lymph nodes of HIV-1-infected patients. We will then
discuss this HIV model in light of the different popula-
tions of macrophages present in distinct tissues and
highlight the critical role of the microenvironment in
tissues such as mucosal tissue and the central nervous
system (CNS).
Activation status of monocytes/macrophages in
peripheral blood and in lymph nodes of HIV-1-infected
subjects
Early in the disease, when the levels of proinflammatory
cytokines, C-C chemokines and type I IFN are low and
chronic immune activation is not yet predominant viral
proteins are crucial for establishing a productive infec-
tion and for the activation of macrophages [147-149].
Viral proteins expressed early in the viral cycle, such as
Nef, Tat, and virion-associated Vpr, activate the TNFR
pathway to partially mimic TNFa biological effects, sug-
gesting that these viral proteins can fuel the progression
of the disease even in the absence of proinflammatory
cytokines, especially in macrophages [9,148,150]. These
viral proteins play a role in the formation of viral reser-
voirs in macrophages by activating transcription from
the LTR and interfering with apoptotic machinery
[6,151]. The classically activated macrophages M1 are in
contact with high levels of Th1 cytokines (IFN-g, IL-2,
IL-12), proinflammatory cytokines (TNFa, IL-1b, IL-6,
IL-18) and chemokines (MIP-1a, MIP-1b, RANTES)
that favor the formation of viral reservoirs with strongly
increased viral transcription and inhibition of HIV-1
entry to block superinfection within infected macro-
phages. In addition type I interferon production is
impaired in primary HIV-1 infection with only limited
inhibition of viral assembling and budding
[147,152,153]. During this stage of the disease M1
macrophages are predominant, tissue injury especially in
lymph nodes is observed and the rate of T-cell apoptosis
is increasing [148].
At a later stage of the disease, a M1 toward M2 shift
is observed with IL-4/IL-13 as pleiotropic modulators of
macrophage activation that induce distinctive pro-
grammes of altered macrophage gene expression after
the engagement of their specific cytokine receptors
[154]. At this intermediate stage M2 macrophages
appear and will favor tissue repair, the MHC class II-
mediated antigen presentation and T-cell activation, the
stimulation of bacterial endocytosis via the up-regulation
of the mannose receptor on the cell surface [2,155].
Alternative activation of macrophages might help to
favor the clearance of opportunistic infections during
HIV-1 disease [156,157]. Intermediate levels of T-cell
apoptosis are observed that does not totally block the
production of proinflammatory cytokines [111,158]. The
combination of IL-4/IL-13 cytokines and proinflamma-
tory cytokines in the microenvironment present in the
vicinity of infected macrophages will curtail the expan-
sion of macrophage HIV-1 reservoirs [38,159].
At the onset of AIDS, T-cell apoptosis is dramatically
increased and opportunistic infections are very frequent
[148,158,160], resulting in an enhanced apoptotic cell
clearance by IL-10-deactivated macrophages [161,162].
An imbalance in the TH1-type and TH2-type responses
has been proposed to contribute to the immune dysre-
gulation associated with HIV infection, and that pro-
gression to AIDS is dependent on a TH1/TH2 shift
[163]. This hypothesis was based on the following facts:
(1) progression to AIDS is characterized by loss of IL-2-
and IFN-gamma production concomitant with increases
in IL-10; and (2) many seronegative, HIV-exposed indi-
viduals generate strong TH1-type responses to HIV
antigens. Recently, haplotypes of the IL-4 and IL-10
genes associated with AIDS progression have been
reported [164,165]. In HIV-infected patients, the amount
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of IL-10, but not IL-4, increases significantly in patients
with AIDS [166]. Opportunistic infections, especially
present at the late stages of the disease, trigger IL-10
production [167] and IL-10 production from patients
with AIDS has been reported to decrease in vitro HIV-1
replication and TNFa production [168]. In addition, IL-
10 has been reported to suppress antiviral T-cell activity
during persistent viral infection [169] and Tat-induced
IL-10 mediates immune suppression during HIV-1
infection [170]. In addition, the IL-10 deactivated
macrophages inhibit the production of proinflammatory
cytokines such as TNFa and C-C chemokines that were
produced abundantly due to chronic immune stimula-
tion during the previous stages of the disease [171,172].
IL-10 inhibits HIV-1 LTR-driven gene expression in
human macrophages through the induction of cyclin T1
proteolysis [173]. At the late stages of the disease the
decreased levels of proinflammatory cytokines result in
a strong reduction of viral transcription. In addition
high expression of IFNa/b inducible proteins such as
APOPEC and TRIM proteins inhibit strongly the HIV-1
reverse transcription and assembly/budding (Table 1).
The deactivation of macrophages also results in a pro-
found immune suppression resulting from the decreased
expression of MHC class II expression on the plasma
membrane of macrophages with diminished Ag-
mediated T cell response and the depletion of both CD4
+ and CD8+ T cell by accelerated apoptosis. Thus, IL-
10 and type I IFN restrict strongly HIV-1 replication in
macrophages parallel to the immune failure observed at
the very late stages of the HIV-1 disease.
Activation status of macrophages in mucosal tissues and
in the CNS
The localization of macrophages in distinct tissues has
been reported to modulate their susceptibility to HIV-1
infection. In human and macaque gastrointestinal
mucosa, most attention has been focused on the small
intestine, where lamina propria CD4+ T cells are promi-
nent HIV-1 and SIV target cells and undergo profound
depletion shortly after infection [174-182]. In contrast,
macrophages in the gastrointestinal mucosa, unlike
monocyte-derived macrophages, are rather resistant to
infection with HIV-1 [183-185]. In contrast to mono-
cytes and monocyte-macrophages, intestinal macro-
phages do not express many innate response receptors
[186,187], are downregulated for triggering receptor
expressed on monocytes (i.e., TREM-1) [188,189] and
costimulatory molecules [187,190], and display markedly
reduced CD4 and CCR5 cell surface protein and mRNA
[191]. Thus, the striking and well-defined phenotypic
and functional differences between blood monocytes
and mucosal macrophages, in particular macrophages in
the gastrointestinal mucosa [186,187,192], preclude the
simple extrapolation from findings in HIV-1-infected
monocytes to HIV-1 infection of mucosal macrophages.
Human vaginal macrophages have been reported
recently to support R5 virus entry in explanted vaginal
mucosa, and purified vaginal macrophages support sub-
stantial levels of R5 HIV-1 replication [193]. Vaginal
macrophages display the innate response receptors
CD14, CD89, CD16, CD32 and CD64, and the CD4
receptor and CCR5 and CXCR4 coreceptors [193]. The
difference in phenotype and HIV-1 permissiveness
between vaginal and intestinal macrophages may reflect
differences in the local microenvironment, since
mucosa-derived cytokines, including TGF-b, regulate the
phenotype and function of blood monocytes after their
recruitment to the mucosa, at least in the intestinal
mucosa [187]. In agreement with this hypothesis, intest-
inal macrophages are threefold less frequently CD4+
CCR5+ than vaginal macrophages, and yet virus is
detected in intestinal macrophages, indicating low-level
receptor mediated entry, but intestinal macrophages do
not support viral replication suggesting a post-entry
block such as described for TGF-b [193].
Macrophages of the central nervous system (CNS) are
permissive to HIV-1 infection. Two models have been
proposed: the Trojan horse model and the late invasive
model [194]. In the Trojan horse model, the virus enters
the CNS early, and replicates at low levels as a reservoir
separated from the periphery. A viral phenotype that is
more virulent in the context of the CNS emerges, lead-
ing to the development of disease. In the late invasion
model, uncontrolled virus replication and resulting
immune deficiency lead to alterations in the myeloid dif-
ferentiation pathway, promoting the expansion of an
activated monocyte subset that is capable of tissue inva-
sion. The hallmark of the brain histopathology is pro-
ductive infection in macrophages (perivascular
macrophages and microglia) [195]. HIV encephalitis
(HIVE) is characterized by monocyte/macrophage infil-
tration into the brain, multinucleated giant cell forma-
tion (fusion of several macrophages), and presence of
microglial nodules [196]. There is little evidence for
infection in neurons, endothelial cells, or macroglia
(astrocytes and oligodendrocytes) [197-199]. In the Tro-
jan horse model, it has been hypothesized that the virus
enters the CNS mainly through infected monocytes and
macrophages destined to become brain-resident macro-
phages or perivascular macrophages [200]. It is assumed
that HIV-1 enters early after primary infection (at a
peak of primary viremia), and HIV-1 infection persists
at low levels due to the immune-privileged status of the
CNS. In addition there is an uniqueness of the brain
microenvironment with several anatomic/structural,
physiological, and immunoregulatory mechanisms that
ensure the immune priviledge of the brain, preventing
Herbein and Varin Retrovirology 2010, 7:33
http://www.retrovirology.com/content/7/1/33
Page 8 of 15
recognition of foreign antigens, to minimize/deviate and
block inflammatory responses [201]. Soluble anti-inflam-
matory molecules have been shown to play a role in
immune privilege in the CNS. TGF-b has the ability to
inhibit activation of macrophages, T lymphocytes, and
NK cells [202], and TGF-b has been shown to possess
neuroprotective capabilities [203]. Upregulation of TGF-
b is observed during HIV-1 infection and is correlated
with the magnitude of inflammatory responses during
HIV-1 brain infection [204]. High concentrations of
gangliosides downregulate expression of MHC class II
on astrocytes [205] and could contribute to generally
low levels of MHC class II on microglia. In contrast, a
significant increase in MHC class II has been reported
in the context of HIVE on activated microglia [206,207]
and it is considered the best neuropathologic correlate
of cognitive impairment [208]. TGF-b, IL-10, and
TRAIL have been reported to contribute significantly to
the CNS-DC-mediated inhibition of allo-T-cell prolifera-
tion [209] and to participate in the control of viral CNS
infections [210]. In agreement with this observation,
only few DC-like cells were found in perivascular spaces
in SIV-infected macaques [211]. Although invasion of
the CNS by HIV-1 occurs at the time of primary infec-
tion and induces a transitory inflammatory process with
increased number of microglial cells, upregulation of
MHC class II antigens, and local production of cyto-
kines [212], viral replication remains very low during
the asymptomatic stage of HIV-1 infection. Specific
immune responses including Th2 cytokines and CTLs
continuously inhibit viral replication at this stage of
infection [213-216]. While HIV-1 enters the brain early
following viral infection [200], detectable productive
viral replication and brain macrophage infiltration occur
years later and only in some infected patients [217]. The
replication of HIV-1 in microglia depends on the micro-
environment in the CNS. Recently, it has been reported
astrocyte-mediated regulation of microglial function and
its influence on the onset and the progression of neu-
roAIDS [218]. HIV-1, recombinant gp120, and viral
transactivator Tat activate astrocytes to secrete pro-
inflammatory cytokines TNFa, IL-6, and IL-1b and the
pro-inflammatory chemokines MCP-1 and IP-10
[195,219-224], all of which could contribute to the over-
all inflammatory environment in the brain. To further
contribute to the inflammatory environment in the
CNS, microglia and macrophages release proinflamma-
tory cytokines such as IL-1b and TNFa which play a
role in CNS injury [225,226]. In agreement with these
data, in vivo expression of proinflammatory cytokines in
HIV-1 encephalitis has been reported and the macro-
phage/microglia lineage is the main cell type reported to
release cytokines in HIVE [227]. Altogether, after an
early and transitory stage of macrophage/microglia
activation at the time of primary infection, a stage of
deactivation of macrophage/microglia is observed paral-
lel to the presence of “deactivating” cytokines such as
TGF-b and IL-10 in the CNS microenvironment. In
some patients, detectable productive viral infection and
brain macrophage infiltration occur years later parallel
to increased levels of pro-inflammatory cytokines in the
context of HIVE.
A M1/M2/Md macrophage polarization model and
vice versa
Altogether, in the lymph nodes of HIV-1-infected
patients a shift from activated to deactivated macro-
phages throughout the disease is observed parallel to a
Th1 pro-inflammatory/Th2 anti-inflammatory switch. In
some tissue such as the intestinal mucosal tissue, the
macrophages are mostly in a deactivated stage with a
local microenvironment curtailing the viral replication
through the release of anti-inflammatory cytokines such
as TGF-b. In contrast to the intestinal mucosa, macro-
phages from the vaginal mucosa are more permissive to
HIV-1 replication and are activated by proinflammatory
cytokines. In the CNS of HIV-infected patients, the
macrophage/microglia are mostly deactivated under the
control of cytokines such as TGF-b, although in some
cases HIVE occurs parallel to the production of proin-
flammatory cytokines and high viral production at
advanced stage of the disease. Thus the shift of macro-
phage/microglia from activation to deactivation and
vice-versa depends on the tissue infected by HIV-1 and
on the local microenvironment. In agreement with this
hypothesis, the reversion of M2/Md macrophages to M1
polarization has been recently reported in vitro, and was
associated with a renewed capacity to support HIV-1
replication [228]. M1/M2/Md macrophage polarization
may represent a mechanism that allows macrophages to
cycle between productive and latent HIV-1 infection
and vice-versa, parallel to the critical role of the tissue
microenvironment which can drive the macrophage
polarization either way and thereby can modulate HIV-1
replication specifically in distinct tissues at different
stages of the disease.
Conclusion
The concept of macrophage heterogeneity and differen-
tiation has been recently highlighted by the description
of at least three types of macrophage activation: M1, M2
and deactivated macrophages. Based on the activation
status of macrophages we propose a model starting with
M1 classically activated macrophages with accelerated
formation of viral reservoirs in a context of Th1 and
proinflammatory cytokines. Then IL-4/IL-13 alterna-
tively activated M2 macrophages will enter into the
game that will be concomitant to tissue repair, enhanced
Herbein and Varin Retrovirology 2010, 7:33
http://www.retrovirology.com/content/7/1/33
Page 9 of 15
MHC class II-mediated antigen presentation, increased
T-cell activation, and enhanced clearance of opportunis-
tic pathogens via bacterial endocytosis. At this stage of
the disease, the expansion of the HIV-1 reservoir in IL-
4/IL-13 alternatively activated M2 macrophages will be
stopped [228]. The M2 macrophages will be in the vici-
nity of Th2 cells with the appearance of IL-10 deactiva-
tion of macrophages leading to immune failure observed
at the very late stages of the HIV-1 disease with dimin-
ished Ag-mediated T cell response and accelerated
depletion of both CD4+ and CD8+ T cells by apoptosis
[229]. A better understanding of the macrophage activa-
tion status during the progression of HIV-1 infection
could lead to the development of new therapeutic
approaches.
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